For the Quarter Ending September 2025
North America
• In USA, the Valsartan Price Index fell by 2.44% quarter-over-quarter in Q3 2025, reflecting destocking pressures.
• The average Valsartan price for the quarter was approximately USD 79546.67/MT reflecting subdued transactional activity and strategic inventory drawdown.
• Valsartan Spot Price softened as import slowdowns and improved logistics reduced freight premiums and selling leverage.
• Valsartan Price Forecast indicates mild near-term softness with potential modest recovery into late Q4 as inventories normalize.
• Valsartan Production Cost Trend showed easing logistics and stable feedstock inputs, marginally relieving upward cost pressure on producers.
• Valsartan Demand Outlook remains weak as buyers delay purchases amid tariff uncertainty and cautious healthcare procurement policies.
• Valsartan Price Index stability hampered by distributor undercutting and spot deals aimed at clearing accumulated inventories quickly.
• Operational restarts and staggered importer restocking may modestly lift demand, but balanced stocks constrain significant price rebounds.
Why did the price of Valsartan change in September 2025 in North America?
• Excess inventories from earlier stockpiling reduced buying urgency, weakening spot demand and pressure on prices.
• Improved logistics and falling freight costs lowered landed costs, enabling sellers to discount, stimulate sales.
• Tariff uncertainty prompted cautious procurement, delaying orders and suppressing immediate demand across pharmaceutical distributors domestically.
APAC
• In China, the Valsartan Price Index fell by 2.397% quarter-over-quarter, driven by export demand weakness.
• The average Valsartan price for the quarter was approximately USD 79400.00/MT, reflecting sustained exporter discounts and inventory clearance.
• Valsartan Price Index shows steady downward pressure as exporters aggressively discount to clear inventories globally.
• Valsartan Spot Price activity remained subdued amid logistics delays and reduced international procurement volumes overall.
• Valsartan Production Cost Trend eased as freight rates declined and input PPI weakness reduced marginal manufacturing expenses.
• Valsartan Demand Outlook remains weak with buyers delaying purchases, favoring inventory drawdown over fresh contracts.
• Valsartan Price Forecast anticipates modest further softening before potential year-end buying partially stabilizes traded levels.
• Valsartan Price Index impacted by port disruptions, holiday season effects, and intensified export competition among Chinese producers.
Why did the price of Valsartan change in September 2025 in APAC?
• Export demand remained muted as buyers consumed inventories and delayed fresh procurement, reducing immediate order volumes.
• Lower freight costs and removal of surcharges eased cost pressures, giving buyers stronger negotiating leverage.
• Stable production alongside rising inventories and occasional logistics delays pressured sellers to cut prices to stimulate offtake.
Europe
• In Germany, the Valsartan Price Index fell by 2.41% quarter-over-quarter, reflecting elevated inventory and subdued activity.
• The average Valsartan price for the quarter was approximately USD 79511.67/MT, supporting cautious buyer patterns.
• Valsartan Spot Price lagged behind contracts as the Valsartan Price Index reflected oversupply and muted buying interest.
• Valsartan Price Forecast indicates modest declines before stabilizing, driven by inventory digestion and buying patterns.
• Valsartan Production Cost Trend remained subdued as freight deferrals and feedstock costs limited upward price pressure.
• Valsartan Demand Outlook stays weak near-term due to adequate stocks and cautious procurement by buyers.
• Export availability from Asia pressured prices, while distributors cleared stock, keeping the Valsartan Price Index soft.
• Maintenance-driven exports and geopolitical shipping risks intermittently influenced availability, moderating any immediate Valsartan price rebounds.
Why did the price of Valsartan change in September 2025 in Europe?
• High inventories and cautious procurement depressed spot activity, reducing urgency and downward pressure on prices.
• Port congestion and deferred PSS limited immediate freight cost escalation, preventing short-term price increases significantly.
• Increased export offers from Chinese suppliers and subdued downstream demand intensified competitive pricing pressure further.
For the Quarter Ending June 2025
North America
• The Valsartan Price Index in the USA showed mixed trends in Q2 2025: declining by 0.99% in April, rising sharply by 3.15% in May, then falling again by 1.05% in June.
• In April, the Product Spot Price softened due to high tariffs (145%) on Chinese imports, strategic frontloading of shipments, and inventory buildup leading to reduced new orders and price cuts to clear stock.
• The Product Production Cost Trend was affected by tariffs, but partial absorption of these costs by supply chain players helped limit price increases in April.
• May saw a significant surge in the Price Index driven by a 90-day tariff suspension on Chinese pharma imports, prompting large-scale procurement and freight capacity strain that increased landed costs.
• The freight logistics bottlenecks, including port congestion and equipment shortages, contributed to higher Valsartan Spot Prices and elevated Product Production Cost Trend in May.
• Demand surged in May as distributors and buyers front-loaded orders ahead of anticipated tariff reinstatements, supported by modest U.S. inflation (0.1%) and expectations of General Rate Increases (GRI).
• June reversed the trend with a declining Price Index, as buyers slowed purchasing due to tariff uncertainty, existing stockpiles, and easing ocean freight rates.
• The Product Demand Outlook weakened in June amid fragile U.S. business and consumer confidence, with usual seasonal demand upticks failing to appear early.
• Mid-year inventory normalization and destocking efforts by pharmaceutical distributors exerted downward pressure on prices during June.
• Price Forecast for July 2025 indicates continued price softness, as demand remains weak with buyers maintaining a cautious “wait and watch” stance, and excess inventory from June further widening the supply-demand gap.
APAC
• The Valsartan Price Index in China fell by 0.99% in April due to weak international demand and ongoing inventory pressure amid disrupted manufacturing and port congestion.
• China’s manufacturing sector contracted sharply in April with the PMI dropping to 49.0, reflecting a deep slowdown that pressured Valsartan production and export logistics.
• U.S. tariffs at 145% heavily dampened export demand, leading to cancellations and half-filled shipments; this forced sellers to offer steep discounts to clear high Valsartan stockpiles.
• Domestic consumption remained sluggish throughout April, compounding the weak Valsartan Demand Outlook and resulting in bearish market sentiment.
• In May, the Valsartan Price Index rebounded sharply by 3.13%, driven by surging international demand as U.S. buyers frontloaded orders ahead of the tariff reprieve expiry.
• Freight capacity tightened and shipping rates rose by 27%, accelerating distribution and firming up prices due to intense competition for container space.
• Exporters saw improved inventory turnover and boosted pricing power amid strong market momentum and narrowing supply.
• June saw a 1.15% decline in the Valsartan Price Index, pressured by overcapacity, falling freight costs, and subdued global demand as buyers delayed purchases expecting lower prices.
• China's Producer Price Index fell 3.6% YoY in June, signaling weak input costs and limited pricing power for Valsartan producers.
• Valsartan Spot Price in July is expected to remain under downward pressure as excess inventories persist and international buyers continue a cautious, “wait and watch” approach despite stable production levels.
Europe
• The Price Index for Valsartan in Germany declined by 0.99% in April, driven by oversupply caused by US tariffs rerouting shipments to Europe and pre-holiday stocking by buyers.
• April’s supply glut, combined with subdued demand, resulted in abundant inventories, pressuring the Product Spot Price downward.
• Logistics disruptions such as port congestion and labor shortages in April constrained demand further, prompting cautious procurement from pharmaceutical buyers.
• In May, the Price Index reversed course, rising sharply by 3.12% due to escalating congestion at Northern European ports and limited vessel capacity, tightening supply availability.
• Anticipation of June’s General Rate Increase (GRI) fueled increased procurement activity and boosted the Product Demand Outlook, encouraging buyers to secure cargo early.
• Shipping reconfigurations shifted capacity back to Trans-Pacific routes, easing European oversupply and supporting upward price momentum in May.
• June saw the Price Index ease by 0.99% amid elevated inventory levels and a more conservative procurement stance, with buyers focused on liquidating stock before mid-year.
• Persistent logistical bottlenecks in June did not translate into immediate freight cost hikes, as carriers postponed Peak Season Surcharges (PSS), contributing to softer pricing.
• The Product Production Cost Trend remained stable, with no significant input cost spikes noted despite ongoing port congestion.
• For July 2025, the Product Price Forecast indicates likely price declines as excess inventory from June continues, demand remains weak, and buyers maintain a wait-and-watch approach, reinforcing the existing supply-demand imbalance.
For the Quarter Ending March 2025
North America
In Q1 2025, Valsartan prices in the USA experienced moderate fluctuations due to various factors. January saw a price increase as U.S. importers rushed to stockpile in anticipation of a 10% tariff on Chinese goods and a potential strike by the International Longshoremen's Association (ILA), which created supply chain concerns. This was further exacerbated by the Chinese Lunar New Year and rising energy costs, contributing to higher operational expenses. However, the ILA strike was cancelled, limiting the impact on prices.
In February, prices declined as supply improved, thanks to higher manufacturing activity in China after the New Year and a decrease in shipping costs. Despite these factors, weak demand due to economic uncertainty and inflationary pressures led to reduced buying activity. In March, prices stabilized, rising slightly by 0.09%. This was largely due to frontloaded purchases in anticipation of new U.S. tariffs, including on Chinese goods, and expectations of further tariff measures.
The overall trend in Q1 2025 was characterized by a mix of cautious procurement, tariff-related uncertainty, and fluctuating supply-demand dynamics.
Asia Pacific
In Q1 2025, Valsartan prices in China experienced a slight upward trend due to a combination of supply constraints and steady demand. In January, prices rose as the pharmaceutical and healthcare sectors drove demand, compounded by a seasonal slowdown ahead of the Lunar New Year, which reduced manufacturing output. Anticipation of U.S. tariffs prompted a rush in exports, further tightening supply. In February, despite the Lunar New Year holiday disruptions, demand remained consistent, and inventory shortages persisted as production resumed slowly. The focus on international markets, especially in response to U.S. tariffs, exacerbated domestic supply constraints. As the month progressed, demand continued to be strong, and suppliers adjusted prices to reflect the limited supply. In March, prices increased marginally as the supply situation slowly improved but could not fully keep pace with growing demand. Domestic and foreign buyers anticipated further tariff actions, prompting early procurement, which added pressure to the already tight market. This combination of factors sustained a bullish market sentiment, with prices edging higher throughout Q1.
Europe
In Q1 2025, Valsartan prices in Germany exhibited notable fluctuations. January saw a moderate price increase due to improved business sentiment and strong demand from the healthcare sector. Optimism in the economic climate, coupled with early inventory restocking ahead of the Lunar New Year, placed upward pressure on prices. In February, prices declined as supply conditions improved, with favorable import conditions driven by a stronger Euro and reduced ocean freight rates. Early stockpiling reduced the need for new orders, while weak demand, fueled by political uncertainty, led suppliers to cut prices to maintain market share. March witnessed a slight price increase, supported by supply-side constraints from port congestion and labor unrest in key European logistics hubs. Renewed restocking activity from cautious buyers, along with improving sentiment in the pharmaceutical sector, helped lift prices. Additionally, a slight decline in Eurozone inflation bolstered confidence among purchasers, allowing suppliers to raise price offers. Overall, Q1 2025 showed a pattern of price increases followed by a decline, with logistical issues and demand fluctuations playing key roles.
For the Quarter Ending December 2024
North America
In the fourth quarter of 2024, Valsartan prices in the United States exhibited significant fluctuations due to a mix of evolving market factors. In October, prices saw a slight increase, fueled by heightened demand as a result of the Federal Reserve's interest rate cuts, which boosted consumer confidence. However, disruptions in the supply chain—such as ongoing port congestion, labor strikes, and the looming threat of tariff hikes under President-elect Donald Trump—intensified pressure on the supply-demand equilibrium, driving prices higher.
By November, a shift occurred as demand began to cool, largely due to inflationary concerns and high interest rates. The U.S. dollar's strength helped reduce import costs, and the resolution of the International Longshoremen’s Association (ILA) strike alleviated some logistical challenges. With inventories remaining well-stocked, suppliers found room to lower their prices, offering some relief to buyers.
In December, the downward price trend continued, spurred by waning consumer confidence, a seasonal dip in demand, and proactive inventory accumulation ahead of expected strikes and the Chinese Lunar New Year. Increased inflation worries and tariff uncertainty led to a more cautious approach by purchasers, while the combination of a healthy supply and competitive pricing kept downward pressure on prices. In sum, Q4 2024 saw a period of price volatility for Valsartan, ultimately trending lower as the quarter came to a close.
Asia Pacific
During the fourth quarter of 2024, the Valsartan market in China experienced notable price fluctuations, shaped by a range of economic factors and market trends. In October, prices increased sightly, driven by a rebound in the country’s manufacturing sector, which was further supported by government stimulus measures. This recovery, combined with rising domestic and export demand fueled by monetary easing and a weakened yuan, boosted consumer confidence. As a result, increased external orders allowed suppliers to raise prices.
However, the situation shifted in November as the market faced an oversupply. High inventory levels, weak domestic demand, and subdued international orders, particularly from the U.S. and Europe, led to a reversal of the upward price trend. The decline in crude oil prices reduced production costs, prompting manufacturers to lower their prices in order to stay competitive in the market.
In December, the downward price movement continued as consumer demand remained lackluster, amid ongoing disinflationary pressures in China. Pharmaceutical companies and international buyers adjusted their procurement strategies, leading to weaker demand. Meanwhile, reduced foreign orders during the holiday season left suppliers with excess stock, prompting them to further cut prices in an effort to clear inventory before year-end. Overall, Q4 2024 witnessed a shift from an initial price increase to subsequent declines, driven by a mix of fluctuating demand and changing market conditions.
Europe
In the fourth quarter of 2024, Valsartan prices in Germany displayed a pattern of volatility. October saw a slight price increase, buoyed by an uptick in business sentiment fueled by hopes for economic recovery and the European Central Bank’s third interest rate reduction to 3.25%. This easing of monetary policy spurred spending and investment. At the same time, ongoing supply chain disruptions at Hamburg’s ports, combined with proactive inventory buildup, exerted additional upward pressure on prices.
By November, the market outlook shifted as demand from end-user sectors weakened, and inflationary pressures started to ease. A noticeable decline in consumer spending and retail activity, coupled with a 1.9% drop in energy costs, led to lower production expenses, allowing suppliers to lower their prices in a bid to remain competitive.
The downward trend continued into December, driven by persistent weak demand from major industries, cautious purchasing behavior due to ongoing inflation concerns, and rising import costs linked to the euro's depreciation. Increased inventory levels and year-end stock clearance efforts further pushed prices downward, while harsh winter weather disrupted logistics and further dampened consumer activity. In summary, Q4 2024 reflected a transition from early optimism to growing economic caution, resulting in a volatile yet generally declining pricing trend.
